News

Uses of Florbetapir PET Scans Set to Take Shape


 

Neurologists are beginning to get their feet wet prescribing the recently approved PET beta-amyloid imaging agent florbetapir (Amyvid), which is now under consideration for Medicare coverage. In this video, our reporter Michele Sullivan takes you through the process of an Amyvid PET scan, which can help rule out Alzheimer’s disease as a cause of cognitive decline.

Recommended Reading

Alzheimer's Imaging Agent Considered for Medicare Coverage
MDedge Neurology
Drugs Set for Testing in Alzheimer's Prevention Trial
MDedge Neurology
Ahead of the Journals: Discontinuing Risperidone in AD
MDedge Neurology
Could Preventing Stroke Protect Against Alzheimer's Disease?
MDedge Neurology
NFL Players Have High Mortality Rate From Alzheimer's Disease and ALS
MDedge Neurology
COMMENTARY—Sports-Related Concussion and Neurodegenerative Disease
MDedge Neurology
Agitation and Psychosis May Speed Progression to Severe Dementia
MDedge Neurology
New and Noteworthy Information—October
MDedge Neurology
Cholinesterase Inhibitor Treatment May Be More Effective for Mild Alzheimer's Disease
MDedge Neurology
Clinical Trial Results Highlight Diverse Ways to Treat Alzheimer's Disease
MDedge Neurology